1

Today1. About Us

• Biz Dev

• Private Placements

• Strategic Advisory

2. Your Needs?3. Next Steps

2

S. Jordan Associates (SJA) is a management consulting firm dedicated to assisting early-stage/growth companies accelerate therapeutic, medical device, and healthcare information technology (HIT) development programs.

Leveraging over 25 years of experience in pharma, biotech, investment banking, and FinTECH (founder of the premier online investment portal HealthiosXchange), SJA has established a strong track record of executing licensing agreements, private placements and “exits” (M&A) on behalf of clients.

Business Development

Strategic Advisory

Private Placements

SJA is affiliated with Healthios Capital Markets, LLC, a registered (FINRA, SEC) registered broker dealer

Abou

t Us

Business Development Strategic Advisory

Private Placements

SJA is affiliated with Healthios Capital Markets, LLC, a registered (FINRA, SEC) registered broker dealer

Abou

t Us

Business Development

“…it’s a widely-held belief that a critical element of exceptional R&D organizations in the future will be creative BD engagement. In short, great BD and R&D are becoming synonymous with each other.” — Bruce Booth, “External Innovation: Force Multiplier for R&D,” Forbes, 6/26/2015

Abou

t Us

“While the list itself is interesting, and each drug could be a blockbuster, I wanted to call attention to something the Goldman report and many others haven’t highlighted directly: the instrumental and essential role of smart business development deal-making underpinning these projects.”

“By my quick review, it appears as though ~75% of these drugs originated at firms different from the company that owns them today – either via licensing deal or via corporate acquisitions. Savvy business development and corporate development strategies drove the bulk of the list.”— Bruce Booth, “Transformational Late Stage Drugs Delivered Through Deal Making,” Forbes, 3/21/2014

“10 Drugs that could transform the industry”

(Jan 2014)

Busi

ness

Dev

elop

men

t: “

Top

10”

Dru

gs

“…it’s no wonder that every big drug company wants to be “Partner of Choice” with smaller innovators. Nearly every pharma has hired consultants at some point to help it position its BD strategy more effectively”

Bruce Booth, “Transformational Late Stage Drugs Delivered Through Deal Making,” Forbes, 3/21/2014

High Potential Pipeline Drugs That Could Transform the Industry

2/3rd’s of the valuation of the industry’s late stage pipelines is from externally derived programs

“10 Drugs that could transform the industry”

(Jan 2014)

Busi

ness

Dev

elop

men

t: “

Top

10”

Dru

gs

“…while the number of VC-backed M&A exits is in line with prior years (~25 per year), the value both in terms of upfront and full “biobuck” (~milestones) potential have reached new highs, topping over $5 and $8 billion, respectively.”

“…the average values per deals are steadily escalating – even though the average invested capital required to get there has remained steady.”

“…these trends have led to a very robust and positive return trend. Return multiples have almost tripled since 2005-2007 on overall deal multiples, and have more than doubled on the upfront multiples.”

BIZ DEV: LANDSCAPE & TRENDS

Bruce Booth, “Data Snapshot: VC-Backed BioPharma M&A 2014,” Forbes, 2/3/15

Busi

ness

Dev

elop

men

t: T

rend

s

“….private VC-funded biotech is a tiny fraction of the scale of the bigger BioPharma part of the sector in every major financial dimension. Small percentile changes to a Big BioPharma company’s market can swamp the scale of the biotech sector…..because of the scale difference, even small changes in the resource allocation practices within large BioPharma companies’ coffer has the potential to dramatically alter the biotech ecosystem. Assume these big BioPharma companies channeled just ~5% of their balance sheet cash into private biotech companies – this capital flow would fully fund the entire VC-backed biotech sector for a year (~50 companies).”

“….this differential in size makes Pharma’s increasing “externalization” of their R&D functions (via partnerships and M&A) a significant financial “buffer” against the cyclic ups and downs of the public capital markets.”

BIZ DEV: EXTERNAL R&D INNOVATION

Bruce Booth, “Data Snapshot: Dwarfed By Big Pharma, Biotech by The Numbers,” Forbes 2/16/15Bu

sine

ss D

evel

opm

ent:

Ext

erna

l R&

D In

nova

tion

CASE STUDY: EXTERNAL R&D INNOVATION

SUMMIT, N.J. & CAMBRIDGE, Mass.--April 15, 2010 -- Celgene Corporation (NASDAQ: CELG) and Agios Pharmaceuticals Inc., a privately-held biotechnology company, today announced the formation of a global strategic collaboration focused on targeting cancer metabolism. The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios’ innovative cancer metabolism research platform. This platform is based on the concept that targeting key metabolic enzymes unique to rapidly proliferating cancer cells can “starve” the cancer.

Terms of the Agreement:

• Under the terms of the agreement, Agios will receive a $130 million upfront payment, including an equity investment

• In return, Celgene receives an initial period of exclusivity during which it has the option to develop any drugs resulting from the Agios cancer metabolism research platform , in addition, Celgene may extend this exclusivity period through additional funding

• If successful, Agios would receive substantial regulatory, clinical and commercial milestones

• Agios will lead discovery and early translational development for all cancer metabolism programs

• Celgene has an exclusive option to license any resulting clinical candidates at the end of Phase I, and will lead and fund global development and commercialization of licensed programs

• On each program, Agios may receive up to $120 million in milestones as well as royalties on sales, and may also participate in the development and commercialization of certain products in the US

“Celgene’s $120M into Agios’ discovery stage story was a surprise then, but looks pretty smart now. It’s equity ownership alone nearly paying for the deal, not to mention product rights.

• A big part of how Agios have done this is via creative business development; their landmark deal with Celgene allowed them to scale with non-dilutive funding during a critical time for the company, which opened up multiple options (and new disease areas to the startup)

• If well structured, less dilutive financing mechanisms via creative collaborations can catalyze significant value creation and optionality for young companies”

Bruce Booth, “Biopharma M&A: Capital Efficiency Drives Returns,” Forbes, 5/15/15

Busi

ness

Dev

elop

men

t: C

elge

ne/A

gios

Capital Efficiency:Most amount of value generated per unit dollar ($) invested

BIZ DEV: CAPITAL EFFICIENCY

Cost of Capital

CapitalIntensity

Rate of Return New Investors Will Demand

Total Amount of Equity Investment Required to Create a Value Inflection

• Initially raised a $33M Series A Round (~Third Rock Ventures) at $2.73/share•Created enough scientific progress to partner with Celgene bringing $120M in largely non-dilutive funding (and some Series B equity)•Celgene deal drove the momentum to raise $75M+ Series C at $13.50/share•Public, raising $106M at $18/share•Agios (AGIO) now trading over $100/share

Bruce Booth “Framing Up Capital Efficiency in Early Stage Biotech,” Forbes, 7/17/2014

“A very clear inverse correlation exits between investor returns and equity capital deployed….M&A values don’t move up proportionally with invested capital. Returns from acquisition-based exits frequently go down with increasing amount of funding.”

Bruce Booth “BioPharma M&A: Capital Efficiency Drives Returns,” Forbes 5/15/15

Busi

ness

Dev

elop

men

t: C

apita

l Effi

cien

cy

12

BUSINESS DEVELOPMENT SERVICES

Abou

t Us

BUSINESS DEVELOPMENT: SJA has an established track record of assisting early-stage/growth companies structure licensing agreements with major BioPharma, Medical Device, and Healthcare Services companies (“Strategics”), including:

1. “Understanding the Process”• “When Should I Partner?”• “Am I Ready to Partner?”•Define Goals Including Timelines• Alternative Corporate Structures (LLC, C-Corp)• Alternative Licensing Structures (Early Pharma Structured

Buyouts)2. Core Document Preparation

• Executive Summary•Management Presentation• Financial Valuation/Modeling

3. Identify, Communicate, Manage Licensing Agreements w/Strategics:

• Identify – SJA “Rolodex” and Big Data (most active companies)• Communicate – Online (email, social media), Offline

(partnering events) •Manage/Due Diligence - Investment Portals

(HealthiosXchange, Capbridge)4. Negotiation

• Term Sheets• Full Agreement

5. Closing, “Win”

Our Track Record:Supervised business development initiatives for IRX Therapeutics

leading to collaboration with a leading pharmaceutical company in 2014

Advised Advanced Life Sciences on securing a licensing partner for the Company’s next-generation antibiotic in Community Acquired Pneumonia (CABP), RestanzaTM/cethromycin, resulting in a Letter of Intent (LOI) from a major Italian pharmaceutical company (2013)

Signed a licensing agreement with Nippon Kayaku, a leading Japanese pharmaceutical company with over $1.2 billion in revenues, for the rights to IL13-PE38QQR (fusion protein - glioblastoma multiforme) on December 28, 2004. NeoPharm received a $3 million upfront payment with potential milestones of $25 million

Identified opportunities for out-licensing NeoPharm’s proprietary liposome drug delivery technology, NeoLipidTM. Signed licensing distribution agreements with Nippon Genetics and Avanti Polar Lipids in 2003-04.

Negotiated a licensing agreement with Wyeth-Ayerst for the rights to NeoPharm’s LErafAON (antisense) in 2002

SJA

Serv

ices

: Bus

ines

s D

evel

opm

ent

“Future of Innovation in the life sciences will be defined by a converging R&D ecosystem that brings larger BioPharma companies, young biotech's, VC’s and academia together in new collaborative models.”

— Bruce Booth, “External Innovation: Force Multiplier For R&D,” Forbes, 6/26/15

CREATIVE DEAL STRUCTURING - EXTERNAL R&D:1. Direct External Innovation Models - Partnering Around a Specific

Company/Project• Venture Co-Creation – Large Pharma/Medical Device participate

with venture capital firms in early moments of launching a company

• Built-to-Buy Deals – Asset-centric drug discovery startups, with pre-defined acquisition rights at Development Company nomination

• Broad Company Accelerating R&D Collaborations – Upfront capital in exchange for pre-specified product rights (e.g. Agios/Celgene)

2. Fund Related Portfolio Approaches – Large Pharma/Medical Device Expand Reach and Exposure to Innovation • Corporate Venture Capital – Syndicate partners of choice in the

early-stage arena• Limited Partnership Commitments – To established venture

funds• Option Funds – Either in-house funds with product rights or LP-

relationships where Pharma/Medical Device gains direct rights to option-in or access the underlying investments in the portfolio

3. Open Innovation Models (Academic Partnerships, Consortia-based Pre-Competitive, Internal Capabilities Sharing)

SJA

Serv

ices

: Bus

ines

s D

evel

opm

ent

“The creation of new startups is vital to the long-term health of biotech.”— Bruce Booth “Venture-Backed Biotech Today, Reflections on Exits, Funding, and Startup Formation” Forbes, 1/22/15

Private Placements

Abou

t Us

Priv

ate

Plac

emen

ts: V

entu

re C

apita

l

Jonathan Norris, Kristina Peralta, “Trends in Healthcare Investments and Exits 2015,” Silicon Valley Bank (SVB)

“Healthcare investment into companies grew significantly, reaching $8.6 billion in 2014. Biopharma companies had the major share of that total, at $6 billion – the highest level since SVB started tracking the data in 2005.”

“We expect increases in fundraising and investment levels will lead to a very active 2015, with a note of caution, however. When the window closes, and non-VC investors pull back, the industry could be left with a crowded private market and lack of investors.”

Priv

ate

Plac

emen

ts: V

entu

re C

apita

l

“….difference between then (1998-2002) and now (2009-2013): in 2000, the number of early-stage investors spiked 75% as the IPO window for biotech began to open up, and stayed high through the collapse of the bubble in 2012. By contrast, the last few years – even with one of the biggest/longest IPO windows in biotech history, have been defined by restraint and constraint in terms of early stage biotech venture and startup formation.”

“Investors participating in BioPharma venture deals declined by ~40%, and never recovered those numbers. This represents a major culling of the herd.”

“Active life science investor numbers (including BioPharma and MedTech) dropped by 25% since 2007, and haven’t rebounded….FLAG Capital Management did a further refinement of “active” investors filtering for only investors that had made at least four new investments with at least $4M in aggregate during 2013, they identified only ~25 active healthcare venture capital investors, and only a subset of those VC’s actually help start or back drug discovery and research stage biotech's – probably only a dozen firms regularly start or fund more than 4-6 new biotech companies a year.”

“The take home message from these data is clear: there’s a huge influx of capital into venture, mostly into technology, and there remains a limited pool of capital flowing into life science venture, and even smaller into early-stage funds – despite the IPO and M&A markets.”

Bruce Booth “Early Stage Biotech Venture Scarcity: Fitness, Fear, and Greed,” Forbes, 9/22/2014 – Data: Dow Jones Venture Source, Franklin Park Associates, NVCA

HOWEVER: “With only ~100 new biotech startups being formed each year, and only a few dozen firms actively doing it, there’s a tiny universe of players responsible for creating the next wave of biotech's likely to mature in the second half of this decade.”

Priv

ate

Plac

emen

ts: C

ross

over

Inve

stor

s

Bruce Booth, “Venture-Backed Biotech Today, Reflections on Exits, Funding, and Startup Formation,” Forbes, 1/22/15 and “Data Snapshot: Venture-Backed Biotech Financing Riding High,” Forbes, 4/21/15

“In the past two years, we have seen the emergence of non-VC investors, particularly hedge funds, providing “top-up” financing to IPO-ready companies prior to entering the market.”

— Jonathan Norris, Kristina Peralta, “Trends in Healthcare Investments and Exits 2015” Silicon Valley Bank (SVB)

“The later-stage financings that have been driving up the aggregate numbers are almost without exception driven by crossover investors

(like hedge funds and mutual funds who typically invest in public companies) or non-traditional partners like financial institutions. For

example, The Alaska Permanent Fund put nearly $300M into Juno Therapeutics during their private round.”

“My estimate, based on discussions with a few bankers who track crossover activity, and an appreciation of Corporate Venture Capital (CVC) contributions, is that only around 50% of the $6B invested in

private biotech's came from “conventional” venture investors (meaning independent venture firms backed by groups of LPs).”

Priv

ate

Plac

emen

ts: C

ross

over

Inve

stor

s

Jonathan Norris, Kristina Peralta, “Trends in Healthcare Investment and Exits 2015” Silicon Valley Bank (SVB)

“Everyone in venture-backed emerging companies acknowledges that going into the public markets with a solid list of blue chip cross-over investors in the capital structure is a good idea conceptually. It makes sense to line up big future owners of the stock early to help support the book-building process in the offering.”

Companies with cross-over led pre-IPO financing rounds have:

• Significantly higher pre-money valuations at IPO (128% higher valuation - $290M vs. 127M)

• Cross-over support IPOs at bigger step-ups in price at IPO (multiple over the last private round valuation is 34% higher)

• Post-IPO stock appreciation vastly outperforms for companies with cross-overs in their pre-IPO round (83% stock appreciation, at the median, versus trading down by 10% without cross-overs)

Bruce Booth, “The Biotech Cross-Over Phenom: Biomarker of Quality?” Forbes, 11/7/2014

Priv

ate

Plac

emen

ts: W

here

is th

e m

oney

goi

ng?

Bruce Booth, “Where Does All That Biotech Venture Capital Go,” Forbes, 2/9/15 - Data Source: HBM; “Venture-Backed Biotech Today, Reflections on Exits, Funding, and Startup Formation,” 1/22/15

NOVEL DRUG TARGETS

“Initial rounds of funding (Series A’s) for novel drug R&D reached their highest levels in a decade in 2013. the importance of “high innovation quotient” investment thesis to gather initial venture funding is clearly on the rise.”

“Over the past decade, nearly 80% of venture capital for therapeutics went toward “novel drug R&D” rather than improvements on existing drugs. This trend is in contrast to the rise of “low technical risk” spec pharma investment model of the 2001-2007 period.”

Priv

ate

Plac

emen

ts: C

orpo

rate

Ven

ture

Cap

ital

EARLY STAGE — CORPORATE VENTURE CAPITAL (CVC)

“Most of the Series A funding of new startups has gone toward early-stage assets (drug discovery, preclinical, and Phase 1), and this has increased over the past five years. Further, the majority of the early-stage financings went to discovery/preclinical (~75%) vs. Phase 1.”

“On the early stage side, nearly one-third of all Series A funding comes from corporate venture capital (CVC) – and this has been increasing over time.”

Bruce Booth, “Where Does All That Biotech Venture Capital Go,” Forbes, 2/9/15 - Data Source: HBM; “Venture-Backed Biotech Today, Reflections on Exits, Funding, and Startup Formation,” 1/22/15

Priv

ate

Plac

emen

ts: F

inTE

CH

In a recent letter to shareholders, JP Morgan CEO Jamie Dimon warned of growing competition for Wall Street in the form of tech start-ups. “Silicon Valley is coming,” Dimon said in the letter, which touched on technologies as varied as mobile payments, bitcoin and peer-to-peer lending. “There are hundreds of start-ups with a lot of brains and money working on various alternatives to traditional banking,” the CEO warned.

“Alternative Finance is a new phenomenon, and it is taking the world by storm. With over 1,250 crowdfunding platforms worldwide, this new model of collaborative funding is breaking boundaries and defying the status quo as to how issuers source capital. In light of this paradigm shift and plethora of platforms, we perceived the need to develop an alternative finance aggregator that would instantaneously display quality private investment opportunities from curated platforms, all in one centralized marketplace.”— “Democratising Finance, Alternative Finance Demystified,” DealIndex, July 2015

BANKING:

PRIVATE PLACEMENTS:

ALTERNATIVE INVESTORS - FINANCIAL TECHNOLOGY (FINTECH)

Source InvestorsONLINE INVESTMENT

MARKETPLACESINVESTORSCOMPANIES Access to Deal Flow

• Business development, private investing, and M&A are moving “online” – while alternative finance started off as seed stage endeavor, more recently platforms have begun to emerge at different stages in the funding cycle, disrupting traditional institutions •Online global investing reached $16.4B in 2014 – over 1,250 crowdfunding platforms worldwide• Alternative finance is drawing more established issuers – Originally seen as a solution to the long-standing funding gap for

early stage companies that appeared in the wake of the 2008 financial crisis, the ability for issuers to raise capital more quickly and at a lower cost than would otherwise be possible at traditional institutions• Alternative finance is removing information barriers and information inefficiencies that exist in the private market, opening

funding conduits an channeling global liquidity

Priv

ate

Plac

emen

ts: F

inTE

CH

• 3,300 members – Accredited Investors, Early- Stage/Growth Company Executives, Investment Professionals, Strategic Buyers

• 600 “Active” healthcare companies in 46 Market Sectors Seeking Licensing Partners, Financings, and/or “Exits”

• Sponsors – Healthios, Chicago-Based Investment Bank and SJA

• The World’s Premier “Direct Investing” Platform

• Sponsored by the Singapore Stock Exchange (SGX), and Venture Capital Firm, Clearbridge Accelerator, and HealthiosXchange

• SGX - Raise, Capital for Small-Medium Size Enterprises (SME), Fund Allocation, Shares depository

24

PRIVATE PLACEMENT SERVICES

Abou

t Us

PRIVATE PLACEMENTS: SJA has successfully raised private placements for early-stage/growth companies via offline (traditional corporate finance/banking), and online platforms (~HealthiosXchange):1. “Understanding the Process”

• Types of Securities: Convertible Notes, Preferred Equity…• Types of Investors: Accredited, Family Office, Institutional…• Regulatory: Filings – Reg D 506 (b), (c) – General Solicitation• Compliance: KYC, Accredited Verification, “Bad Actors”• Custodial: Escrow Accounts• Shareholder Management Post-Close/Reporting

2. Core Document Preparation• Executive Summary•Management Presentation• Financial Valuation/Modeling• Private Placement Memorandum, Subscription Agreement

3. Marketing•Online Investment Portals – Accredited Investors•Offline – Institutional Investors

4. Compliance/eDocuments• Send/Receive Closing Documents ~Docusign• Store in CRM ~SalesForce

5. Funding• Investor Proceeds Secured in Escrow• Escrow Agent Releases Funds to Issuer

5. Shareholder Management• Issuer Makes Available to Shareholders All Closing Documents• File All Necessary Regulatory Reports Post Transaction

Our Track Record:Assisted Healthios with closing and managing client engagements

resulting in over $350MM of invested capital raised in 2013-14 including:

• Clear Vascular• Corium International• Dicerna Pharmaceuticals• IRX Therapeutics• Miacom Diagnostics• Nanomix• Wellfount

In 2012, worked closely with Healthios securing over $50MM of development capital for early-stage/growth companies including:

• Cardiosolutions• Liquidia Technologies• Pinnacle Biologics

Responsible for over 3,000 members joining HealthiosXchange since August of 2013 including:

• Accredited investors• Early-stage/growth company executives• Investment professionals (VC’s, LP’s)• Strategic buyers• Industry association members

Launch of the preeminent global capital markets platform, Capbridge (September, 2015)SJ

A Se

rvic

es: P

rivat

e Pl

acem

ents

“Nearly $26B in real or potentially liquid distributions have been generated over the past two years alone. This is 3-4x more than has been invested over that period of time by VCs into biotech; distributions vastly outstripping investments is certainly positive biomarker for the venture sector.” — Bruce Booth “Venture-Backed Biotech Today, Reflections on Exits, Funding, and Startup Formation” Forbes, 1/22/15

Strategic AdvisoryAbou

t Us

Stra

tegi

c Ad

viso

ry: I

PO o

r M&

A

Bruce Booth, “Tradeoffs and Timing: IPO vs. M&A; A Decision-Making In Biotech,” Forbes, 4/2/15

Assess on behalf of shareholders: Risk/Return Profiles - Sharing downstream

upside with a partner via milestones vs. “Going – Long” in public markets

Time to Liquidity - M&A typically offers realized returns today, whereas IPOs can take years to exit

Dilution – Taking a company public implies selling a piece of the company to others; typical dilution can be 20-40% for an IPO

Stra

tegi

c Ad

viso

ry: I

nitia

l Pub

lic O

fferin

gs

“The number of IPOs at least doubled in each sector and rebounded big exit M&A soared 50%. This environment led to record high potential distributions in 2014, topping $20 billion.”

“This environment led to record high potential distributions in 2014, topping $20 billion. This is the largest return on investment measured since SVB began tracking the information a decade ago.”

Jonathan Norris, Kristina Peralta, “Trends in Healthcare Investments and Exits 2015,” Silicon Valley Bank (SVB)

THE IPO WINDOW IS OPEN!

$25MM Market Cap

San Antonio, Texas- based GenSpera (GNSV) is a biotechnology company engaged in the development of targeted prodrug therapies for the treatment of human solid tumor cancers.

The company’s drug development portfolio is based on a potential first in class, plant derived cytotoxin named thapsigargin, which is isolated from the seeds of a plant that grows naturally in countries around the Mediterranean.

The Company’s lead drug candidate, G-202, is a prodrug formulation of a thapsigargin based cytotoxin that is bioactivated by the enzyme Prostate Specific Membrane Antigen (PSMA).

Stra

tegi

c Ad

viso

ry: P

athw

ays

– Pu

blic

Mar

kets ALTERNATIVE PATHWAYS- GENSPERA

Stra

tegi

c Ad

viso

ry: P

athw

ay to

Pub

lic M

arke

ts

RETAIL INVESTORS OTC.BB NASDAQ?

Investor Keys to Success — Upside, Timeliness & Liquidity• Reasonable Entry Price/Valuation• Likelihood of Steadily Increasing Valuation — Low Burn Rate/Meet Milestone Targets & Dates• Liquidity via Public Listing on OTC.BB — Investors Sell 35% of Position, Recoup Initial Investment• Micro Cap Research Coverage — Increase Trading Volume• Raise Capital Through PIPE with Simultaneous Uplifting to NASDAQ (Meet Market Cap Threshold)• Fund Phase 2 Study — Randomized, Multi-Center, Controlled Study• Projected $1 Billion Valuation with $40 Million Shares; $25/Share (i.e. Plexxikon)• Sale to Strategic — Possible 80-100x Return on Investment within 5-6 Years (i.e. Janssen/Cougar)

Stra

tegi

c Ad

viso

ry: M

erge

rs &

Acq

uisi

tions

Bruce Booth, “Acquisitions As the Silent Partner in Biotech Liquidity: IPO Vs. M&A Exit Paths,” Forbes, 10/27/1014

“By the 2006-2010 period, almost all of the exits, upwards of 75% - regardless of size – were M&A driven events. The recent IPO window (2013/14) pushes the data a bit, but not enough to eliminate the dominance of M&A exits: more than 60% of the big >250M exits in our space in the last few years have been M&A.”

“IPOs used to be the only real game in town. Driving 67% of the exits and over 82% of the >250M exits in the late 1990s.”

“The share of big exits vs. all exits contributed by either path has converged over time. In the last 7 years, roughly identical percentages exits in the two charts above, suggesting that the relative contributions of IPOs and M&As at big and small valuations are similar.”

Stra

tegi

c Ad

viso

ry: M

erge

rs &

Acq

uisi

tions

TWO RECENT SPECTACULAR WINS!

Bruce Booth, “Acquisitions As the Silent Partner in Biotech Liquidity: IPO Vs. M&A Exit Paths,” Forbes, 10/27/1014, NVCA

>20x Cash-on-Cash Return$1.75B >20x Cash-on-Cash Return $725M

Alios acquisition by J&J for $1.75B and Seragon’s purchase by Roche/Genentech for $725M upfront and $1B in earn outs

<7/2011 7/2011 7/2012 11/2013 9/2014

Private Company

Public Company5.5M Shares @ $9/share

FDA Approves RAYOS Acquired US Rights to VIMOVO

Vidara Acquisition Finalized

Domiciled in Ireland - Tax Inv.

Hyperion Acquisition Finalized

5/2015

DUEXSIS® – Arthritis

RAYOS®/LODOTRA – Arthritis (Acquired from Mundipharma)

ACTIMMUNE – CGD (Vidara Acq.)

VIMOVO – Arthritis (Acquired US Rights from AstraZeneca)

RAVICTI & BUPHENYL - Urea

Cycle Disorders (Hyperion

Acquisition)

Investment Banking Team Leadership (Hired From JMP Securities)

• 10 Person Business Development Organization• Analysis: Intellectual Property, Clinical, Commercial• Evaluating 40-50 Transactions Different Simultaneously• Emphasis on “Orphan” Drugs – More Durable Long-Term Asset

Less Competition More Pricing Flexibility

• Focused on acquiring drugs with <$200M in revenues and aggressively promoting to increase sales• Models: NPV, Accretion/Dilution, IRR, PaybackSt

rate

gic

Advi

sory

: IPO

& M

&A

INTERNAL INVESTMENT BANKING TEAM – ACQUISITIONS FUELING REVENUE GROWTH/STOCK PRICE

“Horizon's breakthrough in 2014 wasn't in the lab or a pharmacy; it was in finance.” - Mark Guarino— “The Pain Pill That Saved Horizon Pharma," Chicago Crains, 1/15

Bruce Booth “Data Snapshot: Venture-Backed Biotech Financing Riding High,” Forbes, 4/21/15

“Over time, about 25% of any given quarters’ financings are for newly backed startups (”first financings”); further, the overall number of quarterly biotech financings have been relatively constant at ~120 companies…this implies that the typical life of a venture-backed biotech (at least with regard to their venture financing needs) must be about ~4 years. This data suggest that within that period of time, most biotech's must seal their fate – either via death (shutting down) or by no longer needing venture funding (e.g. IPO, M&A, non-dilutive deal making self sufficiency). Otherwise, if it took a longer time on average to reach that fate, we’d see an increasing pool of biotech companies getting venture financed over time, which we largely haven’t over the past decade.”

Toda

y’s

Chal

leng

e: 4

-Yea

r Tim

e H

oriz

on

BUY-SIDE M&A ENGAGEMENTS1. Identify M&A Targets

• Leverage Technology Platforms (“Big Data”) – SJA has access to over 600+ “Active” (~seeking to transact) emerging growth companies sourced via online portals, HealthiosXchange (U.S. and Europe) and Capbridge (Asia-Pacific)

• Company Breadth – Identify and source companies by market sector (46), financing stage (seed-to-exit), and stage of development (Pre/clinical – Marketed)

• Notifications (“First Mover Advantage”) – "Follow” companies and receive catalysts updates in real-time meaningful to company evaluation/due diligence

SJA

Serv

ices

: Buy

/Sel

l-Sid

e M

&A

SELL-SIDE M&A ENGAGEMENTS1. Identify Strategic Buyers

• “Rolodex”– SJA and investment banking partner, Healthios, have an extensive network of C-level suite executives at leading biopharma, medical device and healthcare services companies

• Events – SJA connects companies and Strategics via online (webinars) and offline (one-on-one’s, conferences, JP Morgan) events

• Online Data Room - SJA provides valued tools for Strategics to efficiently conduct due diligence on companies of interest

Business Development Strategic Advisory

Private Placements

SJA:

Abo

ut U

s Hire SJA as Your “Internal” Investment

Banking Team

Hire SJA to Execute Licensing Agreements with Large

BioPharma, Medical Device, Healthcare Services

Companies

Hire SJA/Healthios to Source Capital

from Institutional and “Alternative” Investors

S. Jordan Associates (SJA) is a management consulting firm dedicated to assisting early-stage/growth companies accelerate therapeutic, medical device, and healthcare information technology (HIT) development programs. Leveraging over 25 years of experience in pharma, biotech, investment banking, and FinTECH (founder of the premier online investment portal, HealthiosXchange), SJA has established a strong track record of executing licensing agreements, private placements and “exits” (M&A) on behalf of clients.

S. Jordan Associates47 W. Division Street

Chicago, IL 60610312-451-6210

scott@sjordanassociates.com@sjordanassociat

http://sjordanassociates.com/

Healthios/HealthiosXchange1101 Skokie

Northbrook, IL 60610847-849-1736

admin@healthios.com@healthiosX

http://www.healthiosxchange.com/

Thank You.

38